Global Dialysis

Dialysis world news

Dialysis to get cheaper in Maharashtra, thanks to tax waiver - Mid-Day

Those suffering from kidney ailments can expect to get cheaper dialysis very soon in Maharashtra, with the state government having decided to waive taxes on its equipment.

According to state finance minister Sudhir Mungantiwar, importing dialysis equipment (dialyser and tubing) has become very expensive because of a 44-per cent import duty. This results in exorbitant charges for the procedure, which needs to be done at least twice a week.

In order to give some relief to patients, the state will no longer demand sales tax or value added tax for the equipment. In the annual budget in March this year, the state government had also waived taxes on medicines for dialysis and kidney-related treatment.

According to information available, diseases like diabetes and high blood pressure are causing kidney issues. Of the total patients suffering from such disorders, some 80 per cent do not get dialysis done, either because it is too expensive or unavailable.

1,000-odd patients die every year because they don’t have access to affordable dialysis centres. In the state, there are 450 dialysis centres that cater to just 17,000 patients. Of these, 250 centres are in Mumbai, where 9,000 patients are treated weekly. Each sitting costs Rs 1500-2000 on average.

There are some charitable institutions that offer heavy discounts to underprivileged patients, but the focus also needs to be on increasing the number of treatment centres, said the minister.

...

Demand for Minimally Invasive Surgeries to Shape the Market for Nephrology and ... - Medgadget.com (blog)

Nephrology and urology are the branches of medicinal science meant to deal with the kidneys and the urinary system and the ailments and intricacies connected with it, their diagnosis (utilization of variety of equipment), and the wide variety of treatments used to treat these complications. Nephrology, specifically, studies the kidneys and urology deals with the urinary system. The U.S. National Institute of Diabetes and Digestive and Kidney Diseases reported that above 2 million kidney stone patients have been diagnosed in the U.S. so far. This rising prevalence of kidney and urinary system ailments will back the development of the market for nephrology and urology devices in the forecast horizon from 2012 to 2018.

The worldwide global nephrology and urology devices market was valued at US$13.3 billion in 2011 and is predicted to reach US$20.5 billion by 2018 expanding at a CAGR of 6.4% between the years 2012 and 2018.

Browse Full Article @ http://www.transparencymarketresearch.com/article/nephrology-and-urology-devices-market.htm

Benign Prostatic Hyperplasia Devices: The Most Swiftly Growing Segment in the Worldwide Nephrology and Urology Devices Market

The global market for nephrology and urology devices is segmented by product type into the segments of urinary stone treatment devices, dialysis devices, urinary incontinence and pelvic organ prolapse treatment devices, endoscopy devices, and benign prostatic hyperplasia (BPH) devices. In 2011, dialysis devices constituted the largest segment in this market, whereas BPH devices are predicted to be the fastest growing segment in the forecasting horizon from 2012 to 2018.

Minimally invasive procedures, the market for which is developing at a rapid pace because of both expense and clinical advantages over conventional treatment routines, are often in demand in the treatment of nephrology and urology diseases. Endoscopy’s visual capacity to control and deal with minimally invasive treatments successfully is spurring physicians into utilizing this innovation for the treatment of urology diseases, such as BPH and kidney stones. The market development is likewise anticipated to be fuelled by the expanding demand for cutting-edge innovations such as capsule endoscopes and video endoscopes.

Europe to Lead Regional Segmentation of the Global Nephrology and Urology Devices Market

The nephrology and urology devices market, based on geography, is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). The European nephrology and urology devices market is the most dominant market; on the other hand, the Asia-Pacific market is expected to be the fastest developing market during the forecast horizon from 2012 to 2018. The advancement of the Asia-Pacific nephrology and urology devices market is liable to be bolstered by solid adoption potential for cutting-edge technologies, because of quickly developing mindfulness about innovation and medical infrastructure in this area.

Get Free Sample @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=286

Aging is the most prevalent factor accountable for a variety of urology ailments. It is predicted that a huge share of the global population will undergo some kind of kidney disease treatment, which will expand the demand for these gadgets all over the world. Persistently enhancing monetary conditions in India, China and Australia will help these nations dedicate significant amounts to cutting-edge healthcare advancements and devices to enhance the overall life quality of their population.

Healthcare providers and hospitals are putting resources into cutting-edge advancements because of the rising medicinal tourism industry, especially in Asian and Middle Eastern nations. Prostatic Hyperplasia is predicted to affect more than 70% of men over the age of 60. BPH is a significant concern for aging males and urinary incontinence is a humiliating consequence for the vast majority. Accordingly, the market for treatment of these conditions is expected to develop throughout the forecasting horizon.

Some of the leading players in the nephrology and urology devices market include Asahi Kasei Corp, B. Braun Group, C. R. Bard Inc., Cook Group Incorporated, Baxter International, Inc., Dornier Medtech, Nikkiso Co., Ltd., Fresenius Medical Care, Nipro Corporation, Nxstage Medical Inc., Rockwell Medical Technologies, Inc, and Terumo Corporation.

Browse Full Global Nephrology and Urology Devices Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/nephrology-and-urology-devices-market.html

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: http://www.transparencymarketresearch.com/

...

Renal Denervation (RDN) Devices Market to Thrive Due to Surge in Hypertension - Medgadget.com (blog)

Renal denervation (RDN) is a minimally invasive procedure used to treat hypertension. Owing to the benefits of RDN devices over drug therapy, the market is projected to grow by leaps and bounds.

Europe Holds Dominant Position in Global RDN Devices Market

Geographically, the global RDN devices market is divided into four main regions: North America, Europe, Asia Pacific, and Rest of the World. With an 80% share in 2012, Europe dominated the worldwide market, followed by Asia Pacific. Europe is also the fastest growing regional renal denervation devices market and is estimated to retain its leading position till 2021. There has been a surge in research and development activities in the field of renal denervation in Europe and numerous devices have gained approval over the past few years. The U.K., France, Italy, and Germany are some of the key RDN devices markets in Europe.

Browse Full Article @ http://www.transparencymarketresearch.com/article/renal-denervation-devices-market.htm

North America, Asia Pacific Emerge as Strong Competitors

FDA approvals for renal denervation devices are projected to rise in the next couple of years, boosting the North America RDN devices market. The increasing incidence of cardiovascular diseases owing to poor lifestyle patterns is another factor that has led to the growing demand for renal denervation devices in the region. Asia Pacific also has a widening patient pool, fuelling the RDN devices market in the region.

Medtronic’s Simplicity Most Widely Used RDN Product

Product-wise, the key renal denervation devices are Boston Scientific’s V2 (Vessix Vascular), Medtronic’s Symplicity, St. Jude’s EnlighHTN, ReCor Medical’s Paradise, and Covidien’s OneShot. Presently, only these five devices have received an approval for CE mark certification. However, no RDN therapy has received approval from the U.S. FDA. In 2012, Medtronic’s Symplicity was the most widely used renal denervation device and held an 85.5% share of the overall market. ReCor Medical’s Paradise is the sole ultrasound denervation system that has a CE certification. Thanks to intense competition among these product manufacturers and the threat of new players, innovative technologies are projected to impact the RDN devices market.

Radiofrequency-based Renal Denervation Devices Hold Largest Share

There are various technologies used in RDN devices such as ultrasound, radiofrequency, micro-infusion, cryoablation, nano-particles, and radiation. Of these, radiofrequency-based renal denervation devices held the largest share of the overall market owing to their benefits of time efficiency, reproducibility, and safety. This segment is projected to continue its dominance over the RDN devices market through 2021. However, the segment is also forecast to face intense competition from other expanding renal denervation technologies.

RDN Devices Market Stimulated by Rising Incidence of Hypertension

The global renal denervation devices market is primarily driven by the growing incidence of uncontrolled hypertension (uHTN) and treatment resistant hypertension (trHTN). An RDN procedure is short and has a permanent effect on the condition of a patient. As a result, the demand for renal denervation devices has gained momentum. Apart from this, the market is also fuelled by the rapid development of renal denervation devices and rise in the global aging population.

Get Free Sample @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=400

Lack of Awareness among Patients Impeding RDN Market

On one hand, there is a shortage of clinical evidence to support the effect of renal denervation devices, which restricts the expansion of the global market. On the other hand, compared to drug-based therapy, there is scant awareness about renal denervation procedures using RDN devices. This, coupled with unstable reimbursement policies, is projected to hamper the growth of the renal denervation devices market.

Renal Denervation Devices Market to Register Outstanding Growth

The global RDN devices market is poised for immense growth till the end of the decade. According to a report by Transparency Market Research, in 2012, the market for renal denervation devices stood at a value of US$88.5 million and is projected to grow to US$1.9 billion by 2021. If this value holds true, the global market will register a CAGR of 41.2% between 2012 and 2021.

Some of the prominent names in the RDN devices market are Boston Scientific Corporation, St. Jude Medical, Kona Medical, Mercator Medsystems, CardioSonic, Medtronic Inc., and Covidien PLC.

Browse Full Global Renal Denervation Devices Market Report With Complete TOC @ http://www.transparencymarketresearch.com/renal-denervation-devices-market.html

...

Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma - Cancer Therapy Advisor

Cancer Therapy Advisor

Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma
Cancer Therapy Advisor
Heterogeneity of decision criteria was observed in most clinical scenarios comparing treatment algorithms in the treatment of metastatic clear cell renal cell carcinoma (mccRCC), according to an article published online in the journal The Oncologist.

...

FMS, THC And UHS, Pushing Health Services Industry Downward - TheStreet.com